Abivax Is the Most Likely M&A Target in Biotech (ABVX:NASDAQ)

Abivax is the most likely M&A target in biotech (ABVX:NASDAQ)

Abivax (ABVX) stock leads biotech M&A prospects for 2026 while Madrigal Pharmaceuticals (MDGL) trails, according to a survey conducted by Truist. Read more here.

Why Abivax Stock Was on Fire Today

Key PointsNew speculation arose about a potential buyout from a very deep-pocketed strategic investor.These first started to swirl in mid-December.10 stocks we like better than Abivax Société Anonyme › France-based biotech Abivax (NASDAQ: ABVX) landed on many investors' buy lists on Monday, following a media report that a giant American peer was interested in acquiring it. With that considerable tailwind at its back, Abivax's share price zoomed …

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abiva…